9Y2 Stock Overview
Engages in the cultivation, production, and distribution of hemp product. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Labocanna S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.055 |
| 52 Week High | zł0.16 |
| 52 Week Low | zł0.051 |
| Beta | 2.98 |
| 1 Month Change | -15.74% |
| 3 Month Change | -23.53% |
| 1 Year Change | -26.42% |
| 3 Year Change | -82.61% |
| 5 Year Change | n/a |
| Change since IPO | -89.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9Y2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.0% | 1.4% | 0.5% |
| 1Y | -26.4% | -16.3% | 7.2% |
Return vs Industry: 9Y2 underperformed the German Pharmaceuticals industry which returned -16.3% over the past year.
Return vs Market: 9Y2 underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 9Y2 volatility | |
|---|---|
| 9Y2 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9Y2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9Y2's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 3 | Pawel Kicinski | labocanna.pl |
Labocanna S.A. engages in the cultivation, production, and distribution of hemp product. The company also offers food and medical hemp-derived products, as well as CBD hemp oil under the Labocanna brand name. Its products are used in cosmetics, plastics, and textiles.
Labocanna S.A. Fundamentals Summary
| 9Y2 fundamental statistics | |
|---|---|
| Market cap | €1.47m |
| Earnings (TTM) | -€70.32k |
| Revenue (TTM) | €99.32k |
14.8x
P/S Ratio-21.0x
P/E RatioIs 9Y2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9Y2 income statement (TTM) | |
|---|---|
| Revenue | zł424.24k |
| Cost of Revenue | zł335.94k |
| Gross Profit | zł88.31k |
| Other Expenses | zł388.67k |
| Earnings | -zł300.36k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 20.82% |
| Net Profit Margin | -70.80% |
| Debt/Equity Ratio | 0% |
How did 9Y2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 12:13 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Labocanna S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|